Digital mammography analysts wait for results
Studies have failed to provide a slam-dunk for digital mammography over traditional film x-rays, according to a recent technology assessment report from the ECRI group.
Studies have failed to provide a slam-dunk for digital mammography over traditional film x-rays, according to a recent technology assessment report from the ECRI group.
ECRI, a nonprofit health services research agency, found that digital mammography's ability to detect breast cancer provides no significant improvement over film mammography.
The report reviewed three previously published screening trials that compared the two technologies: a study by Lewin et al published in the September 2002 issue of the American Journal of Roentgenology and the Oslo I and Oslo II screening trials.
While current research indicates that digital mammography may reduce recall rates as well as follow-up procedures, more evidence is needed to confirm these benefits, the ECRI report said.
Mammographers should wait for the results of the ACRIN trial before jumping into a digital purchase, said Dr. Etta Pisano, chief of breast imaging at the University of North Carolina and principal investigator for the American College of Radiology Imaging Network protocol 6652 trial.
The Digital Mammographic Imaging Screening Trial is the most recent study to compare digital and screen-film mammography. It was not included in the ECRI report. Results will be presented in September at the ACRIN meeting in Washington, DC.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
